Results 101 to 110 of about 1,988,593 (307)

A Rare Presentation of Myeloid Sarcoma as Supraclavicular Mass: A Case Report in Chronic Myeloid Leukemia

Journal of Nobel Medical College
Myeloblasts or immature myeloid cells form myeloid sarcoma, an extramedullary myeloid tumor which commonly affects sites like skin, soft tissues, bone, peritoneum, and lymph nodes.
Amna Khan, Umar Faizan, Syed Ibraheem ul Hassan Ramzi, Ans Javid, Husnain Abbas, Huzafa Ali, Ajay Pandeya, Prerana Maharjan   +7 more
doaj   +1 more source

Penfluridol Triggers GSDME‐Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy

Advanced Science, EarlyView.
A high‐throughput screen of FDA‐approved antipsychotics identifies penfluridol as a potent pyroptosis inducer acting via direct TTI1 inhibition. This triggers TNFA‐NFKB signaling and caspase‐8/‐3‐dependent GSDME cleavage. The compound stimulates antitumor immunity alone and synergizes with anti‐PD‐1 therapy, while low TTI1 expression emerges as a ...
Linfeng Li, Daishi Li, Danyao Chen, Yating Dian, Lei Yao, Hui Su, Ziyu Guo, Deze Zhao, Zihua Wu, Furong Zeng, Chunfang Zhang, Guangtong Deng   +11 more
wiley   +1 more source

Profile of imatinib in pediatric leukemia

Pediatric Health, Medicine and Therapeutics, 2014
Michael J BurkeDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI, USAAbstract: Using targeted therapy for treatment of cancer has become the paradigm to which clinical ...
Burke MJ
doaj  

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

Haematologica, 2013
Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia.
Sarah Abu Kar, Anna Jankowska, Hideki Makishima, Valeria Visconte, Andres Jerez, Yuka Sugimoto, Hideki Muramatsu, Fabiola Traina, Manuel Afable, Kathryn Guinta, Ramon V. Tiu, Bartlomiej Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Mikkael A. Sekeres, Alan F. List, Michael A. McDevitt, Jaroslaw P. Maciejewski   +17 more
doaj   +1 more source

Nilotinib in the Treatment of Chronic Myeloid Leukemia

Future Oncology, 2018
Nilotinib, a second-generation tyrosine kinase inhibitor, was designed to overcome resistance of a wide range of BCR-ABL mutants to imatinib. When used in the first-line treatment in newly diagnosed  chronic myeloid leukemia (CML), it induces faster and deeper molecular responses in higher than imatinib percentage of patients.
Sacha, Tomasz, Saglio, Giuseppe
openaire   +4 more sources

8‐Oxoguanine Modified CircMTUS1 Drives PABPC1 Phase Separation to Promote Gastric Cancer Progression and Cisplatin Resistance via Autophagy

Advanced Science, EarlyView.
ABSTRACT Gastric cancer (GC) is a major global health concern, as its prevention and treatment remain significant challenges. The 8‐oxoguanine (o8G) modification of circRNAs, alongside their capacity to orchestrate liquid‐liquid phase separation (LLPS) and autophagy, plays a pivotal role in driving tumor progression and determining therapeutic outcomes.
Lei Peng, Lurong Li, Zhenghui Zhu, Chenyang Li, Huaiming Sang, Guoxin Zhang, Xuan Li, Yini Dang, Yuanyuan Li   +8 more
wiley   +1 more source

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera

Blood Cancer Journal, 2021
Eliane Nguyen, Michaël Harnois, Lambert Busque, Shireen Sirhan, Sarit Assouline, Ines Chamaki, Harold Olney, Luigina Mollica, Natasha Szuber   +8 more
doaj   +1 more source

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. [PDF]

, 2011
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells.
Carsten Bokemeyer, Balabanov, S., Moll, J., Tessa L. Holyoake, Edgar Jost, Braig, Melanie, Stefan Balabanov, Moll, Jürgen, Rohe, Imke, Gontarewicz, A., Gunhild Keller, von Amsberg, Gunhild, Braig, M., Holyoake, Tessa L., Jost, E., Rohe, I., Jost, Edgar, Bosotti, Roberta, Tim H Brümmendorf, Bosotti, R., Balabanov, Stefan, Barett, Christine, Artur Gontarewicz, Holyoake, T.L., Laura Raddrizzani, Brümmendorf, T.H., Gontarewicz, Artur, Roberta Bosotti, Barett, C., Raddrizzani, Laura, Melanie Braig, Raddrizzani, L., Bokemeyer, C., Jürgen Moll, Tessa L Holyoake, Keller, G., Tim H. Brümmendorf, Bokemeyer, Carsten, Brümmendorf, Tim Henrik, Imke Rohe, Christine Barett   +40 more
core   +2 more sources

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Advanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer, Ian de Ridder, Mahjoobeh Ehsani, Marasim Khan, Justin Kale, Lukas P. Frenzel, David Andrews, Spyridoula Karamanou, Ana J. Garcia‐Saez, Geert Bultynck   +9 more
wiley   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

Hepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou, Kaiwei Jia, Suyuan Wang, Zhenyang Li, Yunhui Li, Shan Lu, Yingyun Yang, Liyuan Zhang, Mu Wang, Yue Dong, Luxin Zhang, Wannian Zhang, Nan Li, Yizhi Yu, Xuetao Cao, Jin Hou   +15 more
wiley   +1 more source